title: [Rheumatoid arthritis and multiple myeloma as comorbidity. Is tocilizumab a therapy option?].
abstract: Multiple myeloma (MM) is a disease of the elderly with an incidence of 4/100,000 per year and can occur as a comorbidity especially in elderly patients with rheumatoid arthritis (RA). For MM and also for RA interleukin-6 (IL-6) is a pathogenetically important cytokine in both disease events. This article presents the case of a female patient who achieved sustained remission of RA and stabilization of MM with quantitative reduction of paraprotein by treatment with tocilizumab. The question whether tocilizumab represents a meaningful treatment approach for treatment of RA when MM is also present will be discussed.
authors.affiliation: Klinik Innere Medizin IV (Rheumatologie, klinische Immunologie und Nephrologie), HSK, Dr.-Horst-Schmidt-Kliniken GmbH, Ludwig-Erhard-Str. 100, 65199, Wiesbaden, Deutschland. norbert.schuetz@hsk-wiesbaden.de
authors.forename: N
authors.initials: N
authors.lastname: Schütz
authors.forename: E
authors.initials: E
authors.lastname: Märker-Hermann
mesh_terms: D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C502936:tocilizumab